近年来，越来越多的研究表明胰岛素样生长因子Ⅰ型受体（insulin-like growth factor-Ⅰreceptor, IGF-ⅠR）在肿瘤的发生和发展中起重要作用，通过抑制IGF-ⅠR信号通路可有效抑制多种肿瘤细胞在体内外增殖。此外，对多种肿瘤细胞的研究也证实，IGF-ⅠR在许多肿瘤细胞表面都上调表达，这使得各种靶向IGF-ⅠR的单克隆抗体不断得到研发，且其中一些已经进入临床研究阶段。此文就IGF-ⅠR结构、IGF-ⅠR在肿瘤发生发展中的作用以及靶向IGF-ⅠR的单克隆抗体的研发和临床应用加以综述。

 In recent years, more and more studies have shown that insulin-like growth factor-Ⅰreceptor (IGF-ⅠR) plays an important role in tumor development and progression, and the inhibition of IGF-ⅠR signal pathway would effectively inhibit many kinds of tumor cells proliferation in vivo and vitro. In addition, the studies of several kinds of tumors confirm that the expression of IGF-ⅠR is up-regulated on tumor cell surface, which the development of monoclonal antibodies targeting IGF-ⅠR. Some monoclonal antibodies have already been tested in a variety of clinical studies. This article discusses the structure of IGF-ⅠR, its physiological function in development and progression of tumors, research and development of monoclonal antibodies targeting IGF-ⅠR and their therapeutic uses.